Palvella Therapeutics Inc. (NASDAQ: PVLA) received approval from Nasdaq to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, the company announced. The transfer took effect at the opening of trading on May 13, 2026.

The company will continue trading under the ticker symbol "PVLA" following the uplisting. The Nasdaq Global Market maintains higher initial and continued listing standards than the Nasdaq Capital Market, including requirements for financial metrics, public float, liquidity, and corporate governance.

"Palvella's uplisting to the Nasdaq Global Market marks an important milestone in the Company's continued progress," said Wes Kaupinen, founder and chief executive officer of Palvella Therapeutics. "As we advance a pipeline of potential first-in-disease therapies, we believe this transition can further elevate Palvella's visibility and support our mission to serve patients suffering from serious, rare skin diseases and vascular malformations."

The Wayne, Pennsylvania-based clinical-stage biopharmaceutical company focuses on developing therapies for serious, rare skin diseases and vascular malformations that currently lack FDA-approved treatments. Palvella's lead product candidate, QTORIN rapamycin, is in development for treating microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas.

The company's second product candidate, QTORIN pitavastatin, is being developed for disseminated superficial actinic porokeratosis treatment. Both products remain investigational and have not received FDA approval.

No action is required from existing shareholders regarding the transfer. Palvella will continue complying with applicable Nasdaq listing standards and Securities and Exchange Commission reporting requirements.